Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for May 2024, reporting a major-holdings notification dated 20 May 2024. The filing concerns GSK plc’s ownership of Haleon, not operating or financial results.
Key financial and ownership metrics
- GSK plc’s resulting voting interest in Haleon: 0%.
- Previous reported voting interest: 4.17%.
- Voting rights held through financial instruments: 0%.
- Total voting rights held after the transaction: 0.
- GSK’s remaining interest was sold through indirectly wholly owned subsidiaries, GSK (No.1) Scottish Limited Partnership and Glaxo Group Limited.
- The shares were held through custodian Vidacos Nominees Limited.
Material changes versus the prior comparable position
GSK’s Haleon voting interest declined from 4.17% to zero after the sale of its entire remaining interest. The threshold was crossed on 17 May 2024, and Haleon was notified on 20 May 2024.
Guidance, outlook, risks and unusual items
The filing provides no revenue, profit, cash-flow, margin, debt, liquidity, guidance or operating outlook information. It does not identify financial contingencies or unusual operating items. The principal corporate event is GSK’s complete exit from its remaining Haleon shareholding.
Investor verification checklist
- Verify the transaction date, 17 May 2024, and completion date, 20 May 2024.
- Confirm that GSK’s reported ownership fell from 4.17% to 0%.
- Review subsequent filings for any changes in Haleon’s shareholder base or secondary-market effects from the disposal.
- Use Haleon’s annual or interim financial filings to assess operating performance, leverage, liquidity and management guidance, which are not covered here.